Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs BCRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AVDL 3 – 3 BCRX Matrix Metrics: AVDL 7 – 3 BCRX

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over BioCryst Pharmaceuticals Inc (BCRX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas BCRX carries 40.6/100 (SELL) at $7.22 (8.4x Forward P/E, 48.8% operating margin).

  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs BCRX
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
BCRX NASDAQ
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.22
-1.37% 1D
Market Cap $1.9B
TTM Revenue $962M
Forward P/E 8.4x
Beta / 30D Vol 0.66β · 42% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 15.0 Fund 48.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.0%), weak momentum, RSI 35
RSI-14: 34.7 · SMA20: $7.83 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (AVDL 3 – 3 BCRX)

Columns: Metric · AVDL · BCRX
1. Valuation Multiples BCRX
Forward P/E 28.8x 8.4x
Trailing P/E 16.8x 12.4x
PEG Ratio 0.07x 9.39x
EV / Revenue 8.5x 2.7x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% +13.1%
Earnings Growth (YoY) +0.0% +133.3%
TTM Revenue (USD) $249M $962M
Market Cap $2.1B $1.9B
3. Profitability & Quality AVDL
Gross Margin 94.9% 78.1%
Operating Margin 2.5% 48.8%
Net Profit Margin -0.1% -37.4%
Return on Equity (ROE) -0.3% -1925.4%
4. Balance Sheet & Cash Flow BCRX
Cash Generation (TTM) $2.7M EBITDA $366M
Cash Flow Margin 1.1% EBITDA Mgn 38.0%
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $687M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVDL
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 2.4% (<1st %ile) 49.4% (10th %ile)
Put/Call OI Skew N/A 0.16x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat BCRX
OpEx & R&D Intensity N/A 29.3% of Rev ($282M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (7) vs BCRX (3)
Institutional Metric AVDL BCRX Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.9B Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x 12.4x Lower Multiple BCRX
Forward P/E Ratio
Valuation
28.8x 8.4x Lower Multiple BCRX
Revenue Growth (YoY)
Growth
+54.9% +13.1% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% 48.8% Higher Margin BCRX
Net Profit Margin
Profitability
-0.1% -37.4% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
-0.3% -1925.4% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 20% ($6–$11) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.66β · 42% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 40.6 / 100 (SELL) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $962M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 78.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev 9.39x PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $366M ($687M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +4.18 pp
AVDL: +0.65% · BCRX: -3.53%
3M Horizon BCRX +5.02 pp
AVDL: -6.32% · BCRX: -1.3%
6M Horizon BCRX +5.02 pp
AVDL: -6.32% · BCRX: -1.3%
1Y Horizon BCRX +5.02 pp
AVDL: -6.32% · BCRX: -1.3%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs BCRX. Trailing 12-month operating profitability (AVDL 2.5% vs BCRX 48.8%) and valuation multiples (AVDL 28.8x vs BCRX 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
BCRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$962M
Gross Margin78.1%
Op. Margin48.8%
ROE / Fwd P/E-1925.4% · 8.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BCRX BREAKDOWN
96d in phase · OBV DISTRIBUTION
Current IV 49.4%
IV Percentile 10th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact BCRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BCRX Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.9B market capitalization and 48.8% operating margin.
OpEx & R&D Reinvestment 29.3% of Rev ($282M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs BCRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over BioCryst Pharmaceuticals Inc (BCRX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas BCRX carries 40.6/100 (SELL) at $7.22 (8.4x Forward P/E, 48.8% operating margin). Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with BCRX at +13.1% YoY revenue growth and +133.3% YoY earnings growth on $962M TTM revenue (78.1% gross margin, 48.8% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $962M for BCRX. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 29.3% of Rev ($282M) (0 disclosures) for BCRX.

BCRX screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas BCRX trades at 8.4x Forward P/E, 12.4x Trailing P/E, 9.39x PEG, and 2.7x EV/Revenue (38.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus BCRX (-1925.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, BCRX carries 49.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.66β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.